Managing Iv Therapy

Managing IV Therapy

Why This Skill Exists

Intravenous therapy is among the most common invasive procedures in healthcare, with over 90% of hospitalized patients receiving some form of IV therapy. The Infusion Nurses Society (INS) Standards of Practice (2021 edition) provide the evidence-based framework for vascular access device (VAD) selection, insertion, maintenance, and complication management. Infiltration and phlebitis are the most common IV complications, while catheter-related bloodstream infections (CRBSI) carry mortality rates of 12–25%. Joint Commission NPSG.07.04.01 (now consolidated under NPSG.07.06.01 for CLABSI) requires evidence-based practices for central line management. CMS considers CLABSI a Hospital-Acquired Condition with reimbursement implications. This skill ensures that nursing management of IV therapy follows INS standards for site assessment, maintenance, complication recognition, and documentation.

Checkpoint A — Intake Verification

Required Patient Information

• Indication for IV therapy (hydration, medication administration, TPN, blood products, hemodynamic monitoring)
• Vascular access history: number of prior attempts, known difficult access, history of DVT or lymphedema affecting access
• Current vascular access inventory: type, location, gauge, insertion date for each device
• Allergy status: latex, chlorhexidine, adhesive tape, iodine
• Anticoagulant status affecting insertion/removal decisions
• Current infusion orders: fluid type, rate, medications, additives, compatibility requirements

Required References

• INS Standards of Practice (current edition)
• Institutional IV therapy policy and procedure manual
• IV medication compatibility reference (Trissel's or institutional equivalent)
• Smart pump drug library with facility-specific entries

Step 1 — Select Appropriate Vascular Access Device

Match device to therapy per INS recommendations:

1. Short peripheral IV catheter (PIV):
   • Duration: < 6 days for most indications
   • Gauge selection: 22–24G for routine hydration/medication; 20G for blood transfusion, CT contrast; 18G for rapid fluid resuscitation, surgical cases
   • Preferred sites: forearm (most stable), hand; avoid antecubital fossa for non-emergent access (limits mobility, higher infiltration risk)
2. Midline catheter:
   • Duration: 1–4 weeks
   • Inserted in upper arm; tip terminates below the axilla, above the antecubital fossa
   • Suitable for: non-vesicant, non-irritant medications with pH 5–9 and osmolality < 900 mOsm/L
3. Peripherally Inserted Central Catheter (PICC):
   • Duration: weeks to months
   • Tip terminates at the cavoatrial junction (confirmed by chest x-ray or intracavitary ECG)
   • Suitable for: vesicants, irritants, TPN, vasoactive medications, prolonged IV antibiotics
4. Central Venous Catheter (CVC):
   • Non-tunneled: short-term ICU use (days to weeks)
   • Tunneled (Hickman, Broviac): long-term use (weeks to months)
   • Implanted port: intermittent long-term access (months to years)
5. Intraosseous (IO): Emergency vascular access when IV access cannot be established within the clinical timeframe

Step 2 — Assess IV Site Per INS Standards

Perform and document IV site assessment at the following intervals:

• PIV: At minimum every 4 hours for adults; every 1–2 hours for pediatrics, neonates, and critically ill; and with each medication administration
• PICC/CVC: Each shift and with each access/use

Assessment Parameters

1. Insertion site inspection: redness, swelling, drainage, tenderness, warmth
2. Dressing integrity: clean, dry, intact, occlusive; transparent dressing allows continuous visualization
3. Securement: catheter stabilization device in place; no tension on tubing
4. Phlebitis assessment using INS Visual Infusion Phlebitis (VIP) Scale:
   • Grade 0: No symptoms
   • Grade 1: Slight pain near IV site or slight redness
   • Grade 2: Pain, redness, and/or swelling at IV site
   • Grade 3: Pain, redness, swelling, palpable venous cord
   • Grade 4: Pain, redness, swelling, palpable venous cord > 1 inch, purulent drainage
5. Infiltration assessment using INS Infiltration Scale:
   • Grade 0: No symptoms
   • Grade 1: Skin blanched, edema < 1 inch, cool to touch, with or without pain
   • Grade 2: Skin blanched, edema 1–6 inches, cool to touch, with or without pain
   • Grade 3: Skin blanched/translucent, gross edema > 6 inches, cool to touch, mild-moderate pain, possible decreased pulses
   • Grade 4: Skin blanched/translucent, tight, leaking, discolored, bruised, swollen, gross edema > 6 inches, deep pitting edema, circulatory impairment, moderate-severe pain; infiltration of blood product, vesicant, or irritant
6. Patency: flush easily without resistance; blood return present; no swelling during flush

Step 3 — Maintain IV Site and Infusion System

1. Dressing changes:
   • Transparent semi-permeable dressing: change every 5–7 days (INS standard) or immediately if soiled, loosened, or damp
   • Gauze dressing: change every 2 days
   • Apply chlorhexidine-based skin antiseptic; allow to dry completely before applying new dressing
2. Tubing changes per INS standards:
   • Continuous infusions: change primary and secondary sets no more frequently than every 96 hours (unless contaminated or integrity compromised)
   • Intermittent infusions: change every 24 hours
   • Blood/blood products: change after each unit or every 4 hours
   • Lipid-containing solutions (TPN with lipids, propofol): change every 24 hours
3. Flushing protocol:
   • PIV: flush with preservative-free 0.9% sodium chloride before and after each use; minimum 3–5 mL
   • PICC/CVC: flush with 10 mL preservative-free 0.9% sodium chloride; lock per institutional protocol (heparin or saline)
   • Use pulsatile flush technique (push-pause) to clear the catheter lumen
4. Needleless connector: scrub with 70% isopropyl alcohol for ≥ 5–15 seconds (per institutional policy); allow to dry; change per manufacturer recommendation (typically every 96 hours or every 7 days with compatible IV sets)

Step 4 — Monitor for and Manage IV Complications

Infiltration/Extravasation

• Stop the infusion immediately
• Aspirate residual fluid from the catheter if possible
• Remove the PIV (do NOT remove if extravasation of a vesicant requiring antidote through the catheter)
• Elevate the affected extremity
• Apply warm or cold compresses per drug-specific protocol
• Administer antidote if vesicant extravasation (e.g., hyaluronidase for vinca alkaloid extravasation, phentolamine for vasopressor extravasation)
• Notify provider; document per institutional incident reporting

Phlebitis (VIP Grade ≥ 2)

• Remove the PIV
• Apply warm compresses
• Restart in a different extremity if IV therapy must continue
• Culture the catheter tip if infectious phlebitis suspected
• Document VIP grade and interventions

Catheter-Related Bloodstream Infection (CRBSI) Suspicion

• Obtain peripheral blood cultures (two sets from two sites) AND culture through the central line (if applicable) BEFORE starting antibiotics
• Notify provider immediately
• Do not remove the catheter until provider decision (some CVC infections can be treated with antibiotic lock therapy)
• Document signs/symptoms, cultures obtained, provider notification

Air Embolism

• Clamp the catheter immediately
• Position patient in left lateral Trendelenburg (Durant's maneuver)
• Administer 100% oxygen
• Call rapid response/code
• Document event details, interventions, patient response

Step 5 — Manage Smart Pump Infusions

1. Program the smart pump using the facility-specific drug library — do not use manual/basic mode for medications in the library
2. Verify all settings against the order: drug, concentration, dose, rate, volume to be infused
3. Respond to all alerts: soft alerts require clinical justification if overridden; hard stops cannot be overridden
4. Document any alert overrides with clinical rationale
5. High-alert infusions (vasopressors, insulin, heparin, sedation) require independent double-check by second RN
6. Monitor infusion site and patient response per drug-specific parameters

Step 6 — Document IV Therapy Management

1. New insertion: date, time, inserter, device type, gauge, location, number of attempts, patient tolerance, blood return/flush verification, dressing applied
2. Shift assessment: site condition (VIP score, infiltration scale), dressing integrity, securement device status, device necessity review
3. Maintenance activities: dressing changes, tubing changes, cap/connector changes with date and time
4. Infusions: fluid/medication name, rate, volume, pump settings, patient response
5. Complications: description, grade (VIP or infiltration scale), interventions, provider notification, outcome
6. Removal: date, time, reason, catheter integrity (tip intact), site condition after removal, hemostasis achieved

Checkpoint B — IV Therapy Review

Shift-Level Verification

• All IV sites assessed and documented with VIP/infiltration scores
• All dressings inspected for integrity
• Smart pump settings verified against current orders
• Device necessity reviewed: remove PIVs not accessed in 24 hours; daily necessity review for central lines
• Infusion compatibility verified for multi-lumen or piggyback administration
• CLABSI prevention bundle compliance documented for central lines

Transition-of-Care Verification

• IV access inventory communicated in handoff report
• Infusion status (rate, volume remaining, next bag timing) communicated
• Pending IV medication times communicated
• Anticipated access needs for next shift identified

Quality Audit

• IV site assessment documented per INS frequency standards (q4h PIV, each shift CVC)
• VIP and infiltration scales used for all assessments (not just "site WNL")
• Dressing changes documented within INS timeframes
• PIV dwell time monitored: replace clinically indicated (not routine 72–96h replacement per INS 2021 update)
• CLABSI prevention bundle compliance ≥ 95% for central lines
• Smart pump drug library compliance ≥ 95%
• Infiltration/extravasation events reported through institutional event reporting system
• Compliant with INS Standards of Practice (current edition)
• Compliant with Joint Commission NPSG.07.06.01 for central line management
• Documentation supports defensibility for any IV-related adverse events

Guidelines

• INS Standards of Practice (2021): The primary evidence-based reference for all vascular access and infusion therapy nursing practice
• Joint Commission NPSG.07.06.01: Evidence-based practices for prevention of CLABSI
• CMS: CLABSI is a Hospital-Acquired Condition; reimbursement implications for hospital-acquired CLABSI
• CDC/HICPAC: Guidelines for Prevention of Intravascular Catheter-Related Infections (2011, updated)
• NDNQI: Peripheral IV infiltration rates are a nursing-sensitive quality indicator
• Device dwell time: INS 2021 recommends clinically indicated removal rather than routine replacement for PIVs; assess for complications rather than replacing on a schedule
• Scope of practice: RN inserts PIVs, manages infusions, and assesses for complications; PICC insertion may be within RN scope with specialty training per state Nurse Practice Act; CVC insertion is a provider procedure; LPN/LVN IV therapy scope varies by state
• Vesicant extravasation: Classified as a sentinel event when resulting in significant harm; requires immediate intervention and incident reporting
• Smart pump safety: Drug library use reduces dosing errors; override rates should be monitored as a safety metric